Wall Street's major averages ended lower on Friday, with the S&P 500 (SP500) and the Nasdaq (COMP:IND) ending the week in the ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Despite last ...
Jim Cramer, the charismatic host of CNBC’s Mad Money, has become a household name for investors seeking bold, actionable ...
Zacks Investment Research on MSN
NVO down 42% year to date: Is this an indication to sell the stock?
Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...
Health-care companies fell as traders weighed risks in a wave of deal activity. Pfizer joined Big Pharma rivals hunting for novel weight loss drugs in the Chinese biotech sector.
Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...
Eli Lilly has surged 47% since my last article, exceeding my previous $800 price target and reaching all-time highs near $1,030. LLY's leadership in the obesity treatment market continues to drive top ...
Eli Lilly is poised to become the first $1 trillion pharmaceutical company, driven by explosive growth in its weight-loss drug, Mounjaro. LLY's earnings and sales growth have been exceptional, with ...
Eli Lilly to invest $6 billion in new synthetic medicine facility in Huntsville, AL to boost domestic production and create ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback